BidaskClub upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a sell rating to a hold rating in a report issued on Thursday, BidAskClub reports.

Other equities analysts have also issued reports about the company. Cowen reaffirmed a buy rating and set a $66.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, January 14th. Guggenheim initiated coverage on ACADIA Pharmaceuticals in a research note on Monday, December 16th. They set a buy rating and a $60.00 price target for the company. Cantor Fitzgerald raised their price objective on ACADIA Pharmaceuticals from $63.00 to $70.00 and gave the stock an overweight rating in a research note on Tuesday, November 26th. JPMorgan Chase & Co. reissued a buy rating on shares of ACADIA Pharmaceuticals in a research note on Sunday, January 19th. Finally, Zacks Investment Research lowered ACADIA Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, December 31st. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. ACADIA Pharmaceuticals has an average rating of Buy and a consensus price target of $52.25.

NASDAQ ACAD traded down $0.78 on Thursday, reaching $46.09. 1,212,319 shares of the stock traded hands, compared to its average volume of 1,389,491. The firm’s fifty day simple moving average is $42.52 and its 200 day simple moving average is $39.44. The company has a quick ratio of 10.89, a current ratio of 10.96 and a debt-to-equity ratio of 0.01. The company has a market cap of $7.10 billion, a price-to-earnings ratio of -26.19 and a beta of 2.82. ACADIA Pharmaceuticals has a 12 month low of $21.56 and a 12 month high of $53.70.

In other news, President Srdjan R. Stankovic sold 2,160 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $46.41, for a total value of $100,245.60. Following the completion of the sale, the president now owns 8,187 shares in the company, valued at $379,958.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen Davis sold 150,000 shares of the stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $52.34, for a total value of $7,851,000.00. Following the completion of the sale, the chief executive officer now owns 152,954 shares of the company’s stock, valued at approximately $8,005,612.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 318,160 shares of company stock valued at $15,583,232. Corporate insiders own 29.40% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACAD. AdvisorNet Financial Inc purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at $27,000. Coastal Investment Advisors Inc. purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at $36,000. PSI Advisors LLC purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $36,000. C M Bidwell & Associates Ltd. purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $37,000. Finally, Whittier Trust Co. purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at $39,000. Institutional investors own 94.64% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Further Reading: What is the Dividend Aristocrat Index?

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.